Solasia Pharma K.K
Research Solasia Pharma K.K (9SO) on Bullrun: market cap EUR 40.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9SO
- ExchangeF
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 40.40M
- Financial periodFY2025
- RevenueJPY 429.00M
- Revenue growth35.8%
- Net income-JPY 876.00M
- Gross margin48.3%
Valuation Snapshot
latest market cap is EUR 40.40M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 429.00M | -JPY 876.00M | n/a | 48.3% | n/a | JPY 1.38B | JPY 16.00M | JPY 1.62B |
| FY2024 | JPY 316.00M | -JPY 1.94B | -JPY 1.03B | 58.5% | -9.77 | JPY 875.00M | JPY 12.00M | JPY 1.04B |
| FY2023 | JPY 617.00M | -JPY 1.11B | -JPY 359.00M | 54.6% | -6.62 | JPY 728.00M | JPY 60.00M | JPY 1.87B |
| FY2022 | JPY 1.09B | -JPY 2.55B | -JPY 2.48B | 60.6% | -16.77 | JPY 803.00M | JPY 37.00M | JPY 2.66B |
| FY2021 | n/a | n/a | -JPY 2.64B | n/a | -19.04 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 40.40M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Solasia Pharma K.K
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Solasia Pharma K.K's market cap?
Solasia Pharma K.K's market capitalization is EUR 40.40M.
What does Solasia Pharma K.K do?
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer.